Introduction: Despite recommendations that general practitioners (GPs) delay antibiotic prescribing for respiratory tract infections (RTIs), antibiotic prescriptions in primary care in England increased by 4.1% from 2010 to 2013. C-reactive protein (CRP) point-of-care tests (POCT), for example, the Afinion TM Analyzer (Alere Ltd, Stockport, UK) device, are widely used in several countries in the European Union. Studies suggest that CRP POCT use, either alone or in combination with communication training, reduces antibiotic prescribing and improves quality of life for patients presenting with RTI symptoms. The aim of this study is to evaluate the costeffectiveness of CRP POCT for RTIs in primary care in England over 3 years for three different strategies of care compared to standard practice. Methods: An economic evaluation was carried out to compare the costs and benefits of three different strategies of CRP testing (GP plus CRP; practice nurse plus CRP; and GP plus CRP and communication training) for patients with RTI symptoms as defined by National Institute for Health and Care Excellence guideline CG69, compared with current standard GP practice without CRP testing. Analysis consisted of a decision tree and Markov model to describe the quality-adjusted life years (QALYs) and cost per 100 patients, together with the number of antibiotic prescriptions and RTIs for each group.
INTRODUCTION
In England, clinical guidance from the National Institute for Health and Care Excellence (NICE) on respiratory tract infection (RTI) recommends that general practitioners (GPs) delay prescribing of antibiotics and advise patients that antibiotics may have no impact on symptoms in suspected viral infections [1] .
Despite this recommendation, antibiotic prescribing increased by 4.1% between 2007
and 2011 in England [2] . As most of these infections are likely to be viral and current evidence suggests that antibiotic prescribing confers no additional benefit [3] , it is likely that most of the prescribing is unnecessary and increases the risk of antibiotic-resistant infections. The Department of Health has developed a 5-year strategy running from 2013 to 2018 in England which aims to slow the development and spread of antimicrobial resistance, by prescribing antibiotics only to patients who are likely to benefit [4] .
C-reactive protein (CRP) point-of-care tests (POCT) are widely used in many European Union (EU) countries for antibiotic prescription decision-making, and a metaanalysis found that they significantly reduce antibiotic prescribing compared to usual care [5] . Other studies have provided evidence that communication training for health-care professionals can be an effective way to reduce the prescription of antibiotics to patients with RTIs [6, 7] . Cost-effectiveness analyses conducted previously have shown that although CRP tests cost more per patient in the short term (€11.27 per patient in Oppong et al. [8] ), this is balanced by a reduction in antibiotic prescriptions (€112.70 per prescription avoided) and improved quality of life [8] .
Evidence of the cost-effectiveness of CRP tests for RTIs versus current practice is limited to analyses alongside trials, none of which look at costs and outcomes beyond 28 days or from the National Health Service (NHS) England perspective.
The aim of this study is to present the results of a decision analytic model of the costeffectiveness of near-patient CRP tests for RTI in NHS England over 3 years.
METHODS

Basic Characteristics of Analysis
The model compares the current standard in GP practice, where patients presenting with RTI symptoms are prescribed antibiotics dependent on GPs' views and patient expectations (hereafter called current practice), and the three different strategies of CRP testing for patients presenting with RTI symptoms: i. GP plus CRP: The patient is tested by the GP using a point-of-care CRP test and prescribed antibiotics accordingly. ii. Practice nurse plus CRP: The patient is tested by the primary care nurse using a point-of-care CRP test and the results passed onto the GP who prescribes antibiotics accordingly. This strategy has been included as a comparator since it is a potential patient pathway considered by GP practices who feel that it might be more reasonable to delegate this responsibility to the practice nurse given the time implications of the CRP test.
iii. GP plus CRP and communication training:
The strategy is the same as (i) GP plus CRP, except that the GP also receives training on communicating with patients about RTI and antibiotics.
It is assumed that, for all three strategies with CRP, the GP receives training on how to use CRP as an aid to diagnosis and how to use the CRP test. Additionally, in strategy (ii) the practice nurse also receives training on CRP.
Model Structure
The economic evaluation consists of a decision tree ( Fig. 1 For all patients the decision tree progresses as follows:
• current practice or one of the three CRP arms;
• antibiotic prescription;
• if prescribed antibiotics, the risk of antibiotic-related adverse events including death;
• complications such as otitis media, quinsy, or sinusitis;
• prescription of antibiotics within 28 days of index consultation;
• complications and adverse events from antibiotic prescriptions within 28 days of index consultation. At baseline, cohorts of 100 hypothetical patients with RTI (with assumed characteristics of adult patients that attend primary care with RTI symptoms, i.e., 50 years old, 62% female [9] ) enter each arm of the four strategies and receive either one of the three CRP test strategies or current practice (no CRP test). They then enter the decision tree ( Fig. 1 ). The probability that a patient is then prescribed antibiotics is dependent on the CRP test or current practice arm of the model they are in.
The probabilities are taken from trial data, but it is likely that prescribing in the CRP test arms is influenced by the results of the CRP test. It is assumed that patients who are prescribed antibiotics then go on to take them.
Antibiotics carry with them a risk of adverse reactions including anaphylactic reaction to penicillin, which carries a risk of death. Not prescribing antibiotics carries the risk of complications including sinusitis, otitis media and quinsy. Antibiotic prescription carries a risk of similar complications, but the risk is lower [1] . The probability that patients have been prescribed antibiotics within 28 days of baseline (the index consultation) has been included in the model along with the costs and complications associated with antibiotic prescription for patients prescribed antibiotics.
The Markov model has only two health states: healthy and RTI. The probability of death is only contained in the decision tree and occurs only for patients who have an adverse event following antibiotic prescription.
Of the two health states in the Markov model, RTI is the only state that contains costs, since it requires a response from the health system.
Patients that enter the RTI health state are only those that attend primary care as a result of RTI symptoms. The decision tree in Fig. 1 is also used in the RTI health state to calculate the probability of antibiotic prescription, antibioticrelated adverse events including death, complications associated with prescribing or delaying antibiotics, and the probability that the patient is prescribed antibiotics within 28 days of the index consultation for this episode of RTI. The probability of being prescribed antibiotics for an RTI after the first cycle in the model (first 28 days) is based on the results of the 3-year study by Cals et al. [9] to reflect the observed change in GP behavior following the index consultation and 28 days follow-up. The two states have health state-specific outcomes, expressed as utility scores used to calculate quality-adjusted life years (QALYs). Three years has been chosen for the duration of the model to reflect the results from the recently published paper by Cals et al. [9] . There is no data available on GP antibiotic prescribing and RTI infections following the implementation of CRP for a time horizon greater than 3 years.
Probabilities: Decision Tree
The probabilities used to populate the decision tree are listed in Table 1 [1, [5] [6] [7] [9] [10] [11] . For the current practice and GP plus CRP arms of the model, the probability of patients presenting with RTI being prescribed antibiotics at the index consultation (baseline) was taken from a systematic review [5] . The results of Little et al. [7] have been added to these, since they were published too late to be included in the systematic review. The probability of antibiotic prescription for practice nurse plus CRP was derived from Cals et al. [10] as that is the pointof-care CRP test protocol used in this study.
Antibiotic prescription at the index consultation for the GP plus CRP and communication training strategy was taken from Cals et al. [10] and Little et al. [7] using the numbers reported in the paper to calculate the percentage of patients prescribed antibiotics.
In the decision tree, patients prescribed antibiotics have a small percentage (0.05%) chance of an adverse event, anaphylactic shock [11] . Patients that have this adverse event have a 10% chance of death [1] . All patients have a percentage chance of complications including sinusitis, otitis media, or quinsy, although the chance of complications is dependent on being prescribed antibiotics at the initial consultation.
All patients also have a probability of being prescribed antibiotics within 28 days of the index consultation, dependent on the arm of the model (current practice or one of the CRP arms). The probability of being prescribed antibiotics within 28 days of the index consultation has been taken from the same studies as baseline (the index consultation) antibiotic prescription, except that no 28-day values were available for Little et al. [7] . Patients prescribed antibiotics within 28 days of the initial consultation also have a percentage chance of antibiotic-related adverse events and complications with the same values as being prescribed antibiotics at baseline.
The same decision tree is also used for patients with incidents of RTI in the subsequent cycles of the Markov model following the first 28 days. The only difference between the first decision tree and decision trees for subsequent incidents of RTI is the probability that patients are prescribed antibiotics when they first attend the GP for this incident of the RTI. The probability that patients are prescribed antibiotics is dependent on the arm of the model and has been taken from 3-year follow-up data in Cals et al. [9] described above. This study does not include a practice nurse plus CRP group and so these values have been assumed to be the same as GP plus CRP.
Probabilities: Markov Model
The transition probabilities used to populate the Markov model are shown in Table 2 [9] . The model replicates RTI rates from Cals et al. [9] over 28-day cycle lengths. The RTI rates are input as the number per person per year and then converted into 28-day probabilities in the model using the formula probability = 1 -exp(rate 9 time period) [12] . At baseline all 100 patients start in the RTI state, and in each cycle all patients that have not died have 28-day transition probabilities for healthy and RTI applied. The health states of patients in preceding cycles are independent of and do not impact on the probability of patients being healthy or having an RTI in subsequent cycles.
As described above, the model assumes that the only way that a patient can die is following an antibiotic-related adverse event. This is captured in the decision tree only and hence no absorbing state of death has been included in the Markov model.
Measuring Costs
The Afinion TM Analyzer (Alere Ltd, Stockport, UK) device [13] is used as the model for the analysis in this study because it is widely used across Europe for CRP testing and also used in England for health assessments including glycated hemoglobin (HbA1c) POCT. The costs included in this model cover the incremental costs of the CRP test and the costs associated with managing an RTI in primary care in the It is assumed that each RTI has an associated weighted cost to the health service per 28 days.
The cost components currently included in the model for each RTI are assumed to be as follows ( • GP practice visit (number of visits, inclusive of the first visit for RTI symptoms);
• out of hours GP consultation (number of visits);
• outpatient attendance (number of attendances);
• hospital admission (number of admissions);
• chest X-ray (number of X-rays); There was no evidence for resource use for the practice nurse plus CRP arm; therefore, the same values have been used as for the GP plus [15, 16] .
Measuring Outcomes
The main outcome measure is QALYs; the number of antibiotics prescribed and the number of RTIs over 3 years were also calculated.
For the measurement of QALYs, each state in the Markov model is assigned a utility score and the total QALYs attributable to treatment depend on the number of patients in each state over the time horizon of the model. The QALYs for RTI health states are dependent on the arm of the model. Patients that experience an adverse event or complication have a utility decrement for that cycle. The utility scores associated with each state currently used in the model are listed in Table 5 [1, 8, 18, 19] . The following assumptions are made regarding the measurement of QALYs in the model:
• the utility score associated with day-to-day health is that of the general population;
• the utility score associated with RTI symptoms is the same for all four arms of the model;
• the utility decrement associated with adverse events and complications is the same for all four arms of the model;
• deaths from antibiotic-related adverse events are assumed to occur on the first day of each cycle; therefore the QALYs associated with each cycle in these states is zero;
• the duration of an RTI is determined by the arm of the model.
When patients are in the RTI state, it is assumed that they are healthy for all days that they do not have an RTI. The QALY for the RTI health state is hence calculated as 28 days, minus the duration of an RTI, times the daily utility score for being healthy plus the duration of an RTI multiplied by the daily utility score for an RTI.
Measuring Cost-Effectiveness
Cost-effectiveness is measured as the net monetary benefit (NMB) of each arm in the model to allow for ranking of the four different The time horizon of the model is 3 years. An annual discount rate of 3.5% for future costs and benefits is used, applied as a discount rate per cycle of 0.26%. All costs are calculated based on prices in 2012/2013, in UK pounds. The analytical perspective is the health service; any cost implications to social services, the individual, the family or employers are excluded.
Values for the total discounted cost and QALYs for each option are provided in Table 5 [1, 8, 18, 19] .
Sensitivity Analysis
Uncertainty in costs and outcomes is investigated in the model with a probabilistic sensitivity analysis (PSA) [20] CRP C-reactive protein, GP general practitioner, NICE National Institute for Health and Care Excellence, PSA probabilistic sensitivity analysis, RTI respiratory tract infection
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RESULTS
Deterministic Analysis
The results of the deterministic analysis are reported in Table 6 . For the deterministic 
Probabilistic Sensitivity Analysis
The results for each of the simulations of the model compared to current practice are presented on a cost-effectiveness plane in Fig. 3 .
The GP plus CRP test strategy is dominant (costs less and results in more QALYs) compared to current practice in 50% of simulations; in 65% of simulations the practice nurse plus CRP test strategy is dominant and in 19% the GP plus CRP and communication training strategy is dominant.
A CEAC comparing the proportion of iterations of the PSA where each option has the highest NMB for a range of values of WTP for a QALY is presented in Fig. 4 given that it is dominated by the other three options.
The results of the one-way sensitivity analysis are presented in Table 7 . Changing most of the key parameters in the model has little impact on the conclusions, except for standardizing the length of RTI. If the length of RTI is standardized across all arms GP plus CRP and communication has a higher NMB than GP plus CRP and current practice, but not practice nurse plus CRP.
The results remain the same for the 9-year time horizon (see Fig. 7 ).
DISCUSSION
Summary of Results
Over a 3-year time horizon, two of the CRP test strategies, GP plus CRP test and practice nurse plus CRP test, have a higher NMB than current practice, although this difference is minimal.
The additional cost per patient of the CRP test is outweighed by the associated cost savings and QALY increment associated with a reduction in infections in the long term. This result is mostly driven by the results of Cals et al. [9] which found that a point-of-care CRP test resulted in reduced risk of RTI per person per year compared to current practice, although the change was not significant.
Although communication training in addition to the GP CRP test also results in 
Strengths and Weaknesses
This is the first study to report the costeffectiveness of different strategies of CRP tests However, the model has some limitations. Firstly, there are limited data on long-term antibiotic prescribing, health-care resource use and incidence of RTI for the point-of-care CRP strategy where the practice nurse conducts the CRP test followed by a consultation with the GP. Instead, the assumption was made that the results are the same as the GP conducting the CRP test and prescribing antibiotics for the missing variables. Given that the cost-effectiveness of the different strategies is strongly driven by these values, it reduces the strength of confidence in these results and the ability to validate the model using another data set.
Secondly, the 3-year follow-up results in Cals et al. [9] only capture the incidence of RTI where patients present to their GP with symptoms. If patients are discouraged from attending their GP because at their index appointment for RTI symptoms they were less likely to be prescribed antibiotics after having received a CRP test, they may perceive there is less value in attending the GP for subsequent RTIs. Hence, the reduced incidence of reported RTI may only be due to reduced primary care attendance, and not an actual reduction in RTI incidence. Although this is correctly reflected in the cost, as less attendance means reduced cost, there is the possibility that some of the disutility of having an RTI might be missing from the CRP arms of the model. 
CONCLUSION
